Retrospective Study of Disease Characteristics and Treatment Response in Patients with Plasma Cell Disorders Classified by Genetic Abnormalities from Fluorescence In Situ Hybridization (FISH)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20251217006

Enrollment

156

Registered

2025-12-17

Start date

2026-01-01

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Plasma Cell Disorders MGUS SMM MM amyloidosis Plasma Cell Disorders MGUS SMM MM amyloidosis Fluorescence In Situ Hybridization FISH

Interventions

Plasma cell disorders who underwent FISH testing

Diagnostic

FISH

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age 18 years or older. 2. Diagnosed with Plasma Cell Disorders, including MGUS, SMM, MM, MGCS, or systemic AL amyloidosis, according to the International Myeloma Working Group (IMWG) diagnostic criteria, between January 2020 and June 2025. 3. Underwent FISH testing before initiation of treatment or at the time of disease relapse.

Exclusion criteria

Exclusion criteria: 1. insufficient data needed for analysis

Design outcomes

Primary

Measure	Time frame
genetic landscape of PCD at diagnosis number and percentage of genetic landscape of FISHin patients with Plasma Cell Disorders	—

Secondary

Measure	Time frame
Response rate at best documented response evaluate from labouratory and imaging result,until best documented response at progression of disease or death the time from maintenance to progression or death,Overall survival at death the time from maintenance to death,Impact of high-risk cytogenetics on prognosis From diagnosis/treatment initiation through entire follow-up period Comparison of PFS and OS between high-risk vs standard-risk cytogenetic groups	—

Measure

Time frame

Response rate at best documented response evaluate from labouratory and imaging result,until best documented response at progression of disease or death the time from maintenance to progression or death,Overall survival at death the time from maintenance to death,Impact of high-risk cytogenetics on prognosis From diagnosis/treatment initiation through entire follow-up period Comparison of PFS and OS between high-risk vs standard-risk cytogenetic groups

—

Countries

Thailand

Contacts

Public ContactChutima Kunacheewa

Faculty of Medicine Siriraj Hospital

chutima.kua@mahidol.ac.th024197767

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026